Fumonisin B2
Based on 1 Customer Validation
Fumonisin B2 is a selective ceramide synthase inhibitor and carcinogenic mycotoxin with toxicity comparable to that of Fumonisin B1 (HY-N6719). Fumonisin B2 inhibits de novo sphingolipid biosynthesis by blocking the amide bond formation between fatty acids and dihydrosphingosine, which leads to a massive intracellular accumulation of free dihydrosphingosine, altered sphingosine levels, subsequent inhibition of cell proliferation, and induction of cell death. Fumonisin B2 is used to investigate the pathogenesis of diseases associated with Fusarium verticillioides contamination, including equine leukoencephalomalacia, porcine pulmonary edema syndrome, human esophageal cancer, and rat hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.99%
- CAS No.: 116355-84-1
- Formule: C34H59NO14
- Masse moléculaire:705.83
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Sphingosine N-acyltransferase[2]
Fumonisin B2 (10-35 μM; 3-5 days) exerts a proliferation-inhibiting effect on LLC-PK1 cells; the cells first exhibit fibroblast-like morphological changes, and this effect is reversible after drug removal[1].
Fumonisin B2 (5 μM; 1 h) binds to lactic acid bacteria (e.g., Lactobacillus paraplantarum CNRZ 1885, Streptococcus thermophilus RAR1) under acidic conditions, with a stronger binding capacity than Fumonisin B1[2].
Fumonisin B2 (7 days of culture; 50 minutes of extraction) is exclusively produced by Aspergillus niger strains NRRL 3122, NRRL 328, NRRL 3 and NRRL 326, with the highest yield observed on Czapek yeast autolysate agar supplemented with 5% NaCl, and no toxin production is detected on malt extract agar[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:42-48-day-old male Sprague-Dawley rats ( 149.1±0.8 g to 181.9±1.3 g)[4]
-
Dosage:0.75 mg/kg
-
Administration:Intraperitoneal injection; once daily; for 2, 4, or 6 days.
-
Result:Showed a significant decrease in body weight only on the last 2 days of the 6-day study.
Significantly reduced the food consumption on the second to last day of the 4-day study and the last 2 days of the 6-day study.
Significantly elevated the serum biochemical parameters including alanine aminotransferase (ALT), creatinine, total protein, IgM, calcium, and magnesium on day 6.
Increased the number of vacuolated bone marrow cells consistently at all time points.
Resulted histopathological changes included single cell necrosis in the liver and kidneys, cytoplasmic vacuolation in the adrenal cortex, and mild to moderate lymphocytolysis in the thymic cortex after 4 and 6 days of exposure.
In the liver, significantly upregulated mRNA expression of p21 and cyclin E genes, while significantly downregulated mRNA expression of p27 and cyclin D1 genes.
There were no significant changes in the protein levels of p27, cyclin E, cyclin D1, and proliferating cell nuclear antigen (PCNA) compared to the control group.
Chemical Information
-
CAS No. 116355-84-1
-
Appearance Solid
-
Masse moléculaire 705.83
-
Formule C34H59NO14
-
Color White to yellow
-
SMILES
OC(C[C@@H](C(O)=O)CC(O[C@@H](C[C@@H](C)CCCCCC[C@@H](O)C[C@H](O)[C@@H](N)C)[C@@H]([C@H](C)CCCC)OC(C[C@H](C(O)=O)CC(O)=O)=O)=O)=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Bondy GS, et al. A comparison of clinical, histopathological and cell-cycle markers in rats receiving the fungal toxins fumonisin B1 or fumonisin B2 by intraperitoneal injection. Food Chem Toxicol. 2000 Oct;38(10):873-86. [Content Brief]
[2]. Yoo HS, et al. Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. Toxicol Appl Pharmacol. 1992 May;114(1):9-15. [Content Brief]
[3]. Niderkorn V, et al. Cell wall component and mycotoxin moieties involved in the binding of fumonisin B1 and B2 by lactic acid bacteria. J Appl Microbiol. 2009 Mar;106(3):977-85. [Content Brief]
[4]. Frisvad JC, et al. Fumonisin B2 production by Aspergillus niger. J Agric Food Chem. 2007 Nov 14;55(23):9727-32. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fumonisin B2 Related Classifications
HY-N6723 Related Classifications
Powered by Bioz